Program
Arsenic Trioxide
Also written as “arsenic trioxide”, “IV Arsenic Trioxide” and “Treatment A: Arsenic Trioxide (ATO) Intravenous”.
Its studies are mostly in Leukemia, Promyelocytic, Acute · Multiple Myeloma · Bronchiolitis Obliterans Syndrome · Leukemia · Leukemia, Myeloid, Acute, led by 6 companies.
Drug pageArsenic Trioxide: every studyMany companies study it; this page follows only the 9 they lead. All 118 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Swedish Orphan Biovitrumits history only | 30 open or running | phase 2since Jun 6, 2001 | Jun 6, 2001 | none ahead |
| SDK Therapeutics | 21 open or running | phase 3since Dec 16, 2025 | Jan 23, 2025 | Jun 2027phase 3 · NCT07296445 |
| Medsenicits history only | 10 open or running | phase 2since Oct 28, 2016 | Oct 28, 2016 | none ahead |
| Oncotherapeuticsits history only | 10 open or running | phase 2since Jun 10, 2004 | Jun 10, 2004 | none ahead |
| Syros Pharmaceuticalsits history only | 10 open or running | phase 1since Aug 3, 2021 | Aug 3, 2021 | none ahead |
| Teva Pharmaceutical Industriesits history only | 10 open or running | phase 3since Aug 6, 2007 | Aug 6, 2007 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of SDK Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 23, 2025First study: phase 1 study in Leukemia, Promyelocytic, AcuteFirst studyNCT06882031 · 12 enrolled · Hong Kong
- Dec 16, 2025Phase 3 study in Leukemia, Promyelocytic, AcutePhase 3 reachedNCT07296445 · 120 planned
Ahead
- Jun 2027Primary completion: phase 3 study in Leukemia, Promyelocytic, AcuteNCT07296445
TargetBeta
“Thioredoxin reductase 1 inhibitor”ChEMBL 37, by rule
Studies
All 2 SDK Therapeutics leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07296445Leukemia, Promyelocytic, Acute | 3 | Not yet recruiting | Jun 2027 | 120 |
| NCT06882031Leukemia, Promyelocytic, Acute · Hong Kong | 1 | Completed | Jun 25, 2025 | 12 |
How it is read
Names in the registry
- “arsenic trioxide”, 4 entries
- “IV Arsenic Trioxide”, 1 entry
- “Treatment A: Arsenic Trioxide (ATO) Intravenous”, 1 entry
- “Treatment B: SDK001 (Arsenic Trioxide Oral solution) under faster state”, 1 entry
- “Treatment C: SDK001 (Arsenic Trioxide Oral solution) under fed state”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Promyelocytic, Acute, 3 studies
- Multiple Myeloma, 3 studies
- Bronchiolitis Obliterans Syndrome, 1 study
- Leukemia, 1 study
- Leukemia, Myeloid, Acute, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.